Mutation Burden Assessment

Mutation burden assessment quantitates genetic alterations predicting immunotherapy response and prognosis. Tumour mutational burden correlates with checkpoint inhibitor efficacy. Next-generation sequencing identifies mutation spectra. Clonal versus subclonal mutation characterisation informs evolution. Mutation burden tracking detects resistance emergence.

Companion diagnostics commercialised with therapeutics identify high-burden patients. Regulatory submissions justify mutation-based stratification. Clinical outcomes stratify by mutation burden. Post-approval monitoring confirms predictive utility. Emerging technologies improve mutation detection.